Speakers

I received my PhD from the University of Edinburgh in 2010, where I studied the interactions between the mental illness risk gene, Disrupted in Schizophrenia 1 (DISC1) and two important neuronal enzymes; PDE4 and GSK3-beta. 

Following my PhD I moved to the USA, where I spent seven years  in the Yale Department of Molecular Psychiatry, working on a range of projects including the first mass-spectrometry proteomic assay of multiple human brain regions, establishing the aged rhesus macaque as a model of early Alzheimer's Disease, and developing cell-type specific techniques for measuring protein translation rates. 

In 2017 I joined Massachusetts General Hospital and Harvard Medical School Neurology, and used proteomic techniques to identify novel tissue and biofluid markers of Alzheimer's Disease and related disorders. After returning to the UK, I was awarded a Senior Research Fellowship from Alzheimer's Research UK to start my own research program in autumn 2022.